Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008

on of cost savings as a result of Project Impact.

Research and development expenses, excluding certain significant items, decreased 1% for the 2008 third quarter versus the 2007 third quarter.

Other (income) expense, net for the 2008 third quarter primarily included costs associated with our foreign exchange hedging program and investment activity, which were partially offset by royalty income and product divestitures. The investment activity included write-downs of Lehman Brothers and Washington Mutual bonds totaling $68.7 million.

The Company's tax rate for the 2008 third quarter, excluding certain significant items, increased to 33.2% from 29.6% in the 2007 third quarter. The increase in the tax rate for the 2008 third quarter versus the 2007 third quarter resulted primarily from certain charges in countries with lower tax rates and the fact that there was no benefit in the 2008 third quarter from the U.S. Research and Development Tax Credit, which had expired in December 2007 but was subsequently renewed on October 3, 2008. The effect of the U.S. Research and Development Tax Credit renewal will be reflected in our 2008 fourth quarter tax rate. Our full year effective tax rate range is still expected to be 29% - 31%.

Net income and diluted earnings per share for the 2008 third quarter were $1,138.4 million and $0.84, respectively, compared with $1,145.9 million and $0.84 for the 2007 third quarter. The 2008 third quarter results included charges of $115.2 million ($79.8 million after-tax or $0.06 per share-diluted) related to the Company's productivity initiative. The 2007 third quarter results included productivity initiative charges of $117.1 million ($86.0 million after-tax or $0.06 per share-diluted). Net income and diluted earnings per share, before these certain significant items, for the 2008 third quarter were $1,218.2 million and $0.90, respectively, compared with $1,231.9 million and $0.90 for the 2007 third quarter.

2
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... CAMBRIDGE, Mass. , May 5, 2015 /PRNewswire/ ... the closing of its initial public offering of ... offering price of $18.00 per share, including shares ... by the underwriters of their option to purchase ... public offering to Blueprint Medicines were approximately $168.6 million, ...
(Date:5/5/2015)... Hayden-McNeil is pleased to announce they ... for smaller courses. This program is specifically designed for ... , “I’m very excited about offering our publishing ... said Jeff McCarthy, Hayden-McNeil president. “By working with more ... to make education both more effective and affordable.” , ...
(Date:5/5/2015)... 5, 2015  Renova™ Therapeutics, a biopharmaceutical company ... and other chronic diseases, has engaged RAND Health ... to reflect the healthcare patterns of multiple advanced ... be used to characterize the impact the company,s ... those groups of patients and the overall health ...
(Date:5/5/2015)... 2015 Franz Inc ., the leading ... that its flagship product, AllegroGraph, has been named a Champion ... Update report. AllegroGraph is a high performance Semantic ... standards. Graph databases are skyrocketing in popularity and have grown ... recent DBMS ranking by DB-Engines. , “We are ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... Johnson & Johnson (NYSE: JNJ ) ... of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that ... is expected to operate as a stand-alone entity reporting ... Johnson & Johnson , Caring for the world, ...
... SUNNYVALE, Calif., Dec. 30 Accuray Incorporated,(Nasdaq: ARAY ... today,that its president and chief executive officer, Euan S. Thomson, ... Healthcare Conference in San,Francisco, on Wednesday, January 14, 2009 at ... A live webcast of the presentation will be available ...
... and PHILADELPHIA, Pennsylvania,December 29 Rosetta Genomics, ... molecular diagnostics, announced,today the introduction of its ... now commercially available through Rosetta Genomics CLIA-certified,lab ... To order the test, physicians may contact ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at 27th Annual JP Morgan Healthcare Conference 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 4Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 5
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... A major factor in the advance of heart disease is ... of scientists at Temple University School of Medicine,s (TUSM) Center ... Now, the researchers are one step closer to achieving that ... an unexpected place in heart cells mitochondria, tiny energy ...
... adding statistical nuance to our understanding of how modern ... model of Arctic temperature and how it relates to ... and lake sediments, Martin Tingley, a research associate in ... Huybers, Professor of Earth and Planetary Sciences, have shown ...
... and biomolecular engineering professor,s theories on crystal formation will ... Professor Peter Vekilov received a grant from NASA to ... form crystals. While researchers understand how crystals grow, they ... liquid to crystal. Vekilov discovered in 2004 that ...
Cached Biology News:Clues to heart disease in unexpected places, Temple researchers discover 2Clues to heart disease in unexpected places, Temple researchers discover 3New research helps place modern temperatures into a more complete statistical framework 2University of Houston engineering researcher's theories to be tested in space 2
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... The MAX POWER 500V Programmable ... operate instruments which can handle virtually ... to high current blotting. It is ... text displays. The MAX POWER Programmable ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
...
Biology Products: